# Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

> **NCT00318747** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 140 (—)

## Conditions studied

- Asthma
- Allergy
- Allergic Rhinitis
- Rhinitis, Allergic, Seasonal

## Interventions

- **DRUG:** Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)

## Key facts

- **NCT ID:** NCT00318747
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 140 (—)
- **Why stopped:** Poor enrollment
- **Last updated:** 2013-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318747, "Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00318747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*